CDIAC to CADTH:
How the pan-Canadian Oncology Drug Review (pCODR) is changing to accommodate provincial cancer agency needs
Date held: March 14th, 2019
Presented by: Gerry Jeffcott, 3Sicty Public Affairs with guest panelists Louise Binder & Martine Elias
This webinar was hosted by Gerry Jeffcott from 3Sixty Public Affairs. He summarized some important changes that the Canadian Agency for Drugs and Technologies in Health (CADTH) has proposed to the way pCODR reviews new cancer medications and outline the current consultation process. Following the CADTH summary, patient representatives Louise Binder (Save Your Skin Foundation) and Martine Elias (Myeloma Canada) offered their perspective on the proposals and helped frame the patient feedback.
After hearing from CADTH and the patients, there was time for an interactive question and answer session.
In particular, the presentation covered the following topics:
- A summary of the Cancer Drug Implementation Advisory Committee (CDIAC) role and function in the cancer medication evaluation process
- A review of how CADTH proposes to embed the CDIAC’s work into its pCODR process
- Patient perspectives on the proposed changes
The slides are available on our Slideshare account here.